33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4871)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Maximal tolerated dose determined for venetoclax in combination with liposomal vincristine in patients with relapsed or refractory ph- negative T-cell or B-cell acute lymphoblastic leukemia: Results of phase 1 portion of ECOG-ACRIN EA9152
    Meeting Abstract

    Palmisiano, N.; Lee, J. W.; Claxton, D. F.; Paietta, E.; Alkhateeb, H. B.; Park, J. H.; Podoltsev, N.; Atallah, E. L.; Schaar, D. G.; Dinner, S.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • A comparison of clinical outcomes from updated ZUMA-5 (axicabtagene ciloleucel) and the international SCHOLAR-5 external control cohort in relapsed/refractory follicular lymphoma (R/R FL)
    Meeting Abstract

    Palomba, M. L.; Ghione, P.; Patel, A. R.; Deighton, K.; Jacobson, C.; Nahas, M.; Jung, A. S.; Hatswell, A. J.; Kanters, S.; Limbrick-Oldfield, E.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Ex vivo T-cell receptor αβ (+)/CD19 (+)depletion of peripheral stem cell grafts for pediatric patients with bone marrow failure (BMF) undergoing unrelated donor transplantation
    Meeting Abstract

    Oved, J. H.; Elgarten, C. W.; Wang, Y.; Kadauke, S.; Monos, D. S.; Barrett, D. M.; Grupp, S. A.; Bunin, N.; Olson, T. S.
    Blood (2021)

    Fulltext@MSK | Save
  • Tafasitamab plus lenalidomide versus pola-BR, R2, and CAR T: Comparing outcomes from RE-MIND2, an observational, retrospective cohort study in relapsed/refractory diffuse large B-cell lymphoma
    Meeting Abstract

    Nowakowski, G. S.; Yoon, D. H.; Mondello, P.; Joffe, E.; Fleury, I.; Peters, A.; Greil, R.; Ku, M.; Marks, R.; Kim, K.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • CD229 CAR T cell therapy for the treatment of relapsed B cell lymphoma
    Meeting Abstract

    Olson, M.; Luetkens, T.; Iglesias, F.; Radhakrishnan, S.; Law, J. Y.; Avila, S.; Mause, E. V.; Camp, N. J.; Morales, E.; Rapoport, A. P.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Pediatric patients with immune thrombocytopenic purpura have a dysbiotic gut microbiome at time of diagnosis
    Meeting Abstract

    Oved, J. H.; Elgarten, C. W.; Daniel, S. G.; Denu, L.; Silverman, M.; Bittinger, K.; Olson, T. S.; Lambert, M. P.
    Blood (2021)

    Fulltext@MSK | Save
  • Allogeneic transplantation in fit older adults is feasible and encouragingly efficacious. Post remission data from the prospective ECOG-ACRIN (E2906) clinical study
    Meeting Abstract

    Ofran, Y.; Sun, Z.; Rowe, J. M.; Claxton, D. F.; Tallman, M. S.; Arber, D. A.; Melnick, A.; Levine, R. L.; Paietta, E.; Godwin, J. E.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Enrollment characteristics and outcomes of Hispanic and Black AYA ALL patients enrolled on a US Intergroup clinical trial: A comparison of the CALGB 10403 (alliance) cohort with us population-level data
    Meeting Abstract

    Muffly, L.; Yin, J.; Jacobson, S.; Advani, A.; Luger, S. M.; Tallman, M. S.; Litzow, M. R.; Foster, M. C.; Appelbaum, F. R.; Larson, R. A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Complete remission with devimistat (CPI-613) in refractory Burkitt lymphoma
    Meeting Abstract

    Nikolaenko, L.; Pardee, T.; Steiner, R.; Abramson, J. S.; Horwitz, S. M.; Matasar, M. J.; Owens, C.; Rodriguez-Rivera, I.; Straus, D. J.; Luther, S.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • High throughput single-cell simultaneous genotyping and chromatin accessibility reveals genotype to phenotype relationship in human myeloproliferation
    Meeting Abstract

    Myers, R. M.; Izzo, F.; Prieto, T.; Mimitou, E.; Raviram, R.; Chaligne, R.; Hoffman, R.; Stahl, M.; Abdel-Wahab, O.; Marcellino, B.; more...
    Blood (2021)

    Fulltext@MSK | Save